Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean glycol and hyaluron acid non animalis stabilized and retinal?
Displaying drugs 15101 - 15125 of 15190 in total

CRA_1801

Experimental

(3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine

Experimental

2,5-bis-O-{3-[amino(imino)methyl]phenyl}-1,4:3,6-dianhydro-D-glucitol

Experimental

2-O-(4'-AMIDINOPHENYL)-5-O-(3''-AMIDINOPHENYL)-1,4:3,6-DIANHYDRO-D-SORBITOL

Experimental

2,5-O,O-BIS-{4',4''-AMIDINOPHENYL}-1,4:3,6-DIANHYDRO-D-SORBITOL

Experimental

1,4:3,6-Dianhydro-2-O-(3-carbamimidoylphenyl)-5-O-(4-carbamimidoylphenyl)-D-glucitol

Experimental

18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE

Experimental

ZK-806711

Experimental

(4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one

Experimental

Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone

Experimental

Atpenin A5

Experimental

5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone

Experimental

Metizoline

Experimental

(2S)-2-methyl-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine

Experimental

ZK-805623

Experimental

(4R,5S,6S,7R)-1,3-dibenzyl-4,7-bis(phenoxymethyl)-5,6-dihydroxy-1,3 diazepan-2-one

Experimental

CRA_10655

Experimental

4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM

Experimental

GO-203-2C

GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Matched Iupac: … hydroxypentylidene]amino}-1-hydroxypentylidene]amino}-1-hydroxyhexylidene]amino}-3-(C-hydroxycarbonimidoyl)propanoic acid …

CRA_9785

Experimental

CRA_10656

Experimental

1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)-6-HYDROXYPYRIMIDINE-2,4(1H,3H)-DIONE

Experimental

2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine

Experimental

6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidine

Experimental

XL019

XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.
Investigational
Displaying drugs 15101 - 15125 of 15190 in total